Salvador Quiroz-González , Erika Elizabeth Rodríguez-Torres , Ismael Jiménez-Estrada
{"title":"Modulating neuroinflammation through electroacupuncture: Mechanistic insights and pharmacological synergies","authors":"Salvador Quiroz-González , Erika Elizabeth Rodríguez-Torres , Ismael Jiménez-Estrada","doi":"10.1016/j.coph.2025.102564","DOIUrl":null,"url":null,"abstract":"<div><div>Neuroinflammation plays a central role in the pathogenesis of numerous neurological and neurodegenerative diseases, driven by complex interactions among glial activation, cytokine release, blood–brain barrier (BBB) dysfunction, and autonomic dysregulation. While pharmacological therapies targeting inflammatory mediators show promise, their efficacy is often limited by poor BBB permeability and systemic side effects. Electroacupuncture (EA), a neuromodulatory technique that combines acupuncture with electrical stimulation, has emerged as a promising adjunctive intervention for modulating neuroimmune dynamics. EA activates defined somatosensory afferents and transmits signals to key autonomic and limbic nuclei, including the brainstem and hypothalamus, which regulate immune responses. At the molecular level, EA suppresses pro-inflammatory pathways such as TLR4/NF- κB and NLRP3 inflammasome activation while promoting anti-inflammatory signaling via the JAK2/STAT3 and PI3K/Akt pathways. It also influences microglial polarization toward the reparative M2 phenotype and modulates BBB permeability and gut–brain axis interactions. Notably, EA has demonstrated synergistic potential when combined with pharmacologic agents such as <span>l</span>-DOPA, selegiline, donepezil, and minocycline, enhancing neuroprotective efficacy and reducing inflammatory and oxidative burdens. This highlights EA's potential integration into clinical strategies for treating neurodegenerative disorders. Understanding the neural circuits and immunological cascades engaged by EA may inform its future integration with pharmacotherapy in personalized neuroimmune interventions.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"Article 102564"},"PeriodicalIF":4.2000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471489225000608","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Neuroinflammation plays a central role in the pathogenesis of numerous neurological and neurodegenerative diseases, driven by complex interactions among glial activation, cytokine release, blood–brain barrier (BBB) dysfunction, and autonomic dysregulation. While pharmacological therapies targeting inflammatory mediators show promise, their efficacy is often limited by poor BBB permeability and systemic side effects. Electroacupuncture (EA), a neuromodulatory technique that combines acupuncture with electrical stimulation, has emerged as a promising adjunctive intervention for modulating neuroimmune dynamics. EA activates defined somatosensory afferents and transmits signals to key autonomic and limbic nuclei, including the brainstem and hypothalamus, which regulate immune responses. At the molecular level, EA suppresses pro-inflammatory pathways such as TLR4/NF- κB and NLRP3 inflammasome activation while promoting anti-inflammatory signaling via the JAK2/STAT3 and PI3K/Akt pathways. It also influences microglial polarization toward the reparative M2 phenotype and modulates BBB permeability and gut–brain axis interactions. Notably, EA has demonstrated synergistic potential when combined with pharmacologic agents such as l-DOPA, selegiline, donepezil, and minocycline, enhancing neuroprotective efficacy and reducing inflammatory and oxidative burdens. This highlights EA's potential integration into clinical strategies for treating neurodegenerative disorders. Understanding the neural circuits and immunological cascades engaged by EA may inform its future integration with pharmacotherapy in personalized neuroimmune interventions.
期刊介绍:
Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.